IDEXX Laboratories, Inc. $IDXX is TimesSquare Capital Management LLC’s 6th Largest Position

TimesSquare Capital Management LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 192,938 shares of the company’s stock after selling 8,338 shares during the quarter. IDEXX Laboratories makes up about 1.8% of TimesSquare Capital Management LLC’s investment portfolio, making the stock its 6th largest position. TimesSquare Capital Management LLC owned about 0.24% of IDEXX Laboratories worth $123,266,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter worth about $30,000. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $31,000. Armstrong Advisory Group Inc. increased its position in shares of IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares during the last quarter. Salomon & Ludwin LLC purchased a new stake in shares of IDEXX Laboratories in the third quarter valued at $35,000. Finally, Greykasell Wealth Strategies Inc. purchased a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $35,000. Institutional investors own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other news, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the sale, the executive vice president owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Trading Up 2.0%

Shares of IDEXX Laboratories stock opened at $629.35 on Friday. The firm has a market capitalization of $50.25 billion, a price-to-earnings ratio of 48.15, a PEG ratio of 3.83 and a beta of 1.67. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The stock has a 50 day moving average of $684.99 and a 200 day moving average of $667.68.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. UBS Group decreased their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research report on Tuesday, February 3rd. JPMorgan Chase & Co. lifted their price objective on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Barclays dropped their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, Jefferies Financial Group restated a “buy” rating and set a $830.00 target price on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.